IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10959938 B1

PDFFull Text
Date of Patent:
Mar. 30, 2021

Filed:

Dec. 21, 2012

Combination of (3s,3s') 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Applicants:

Quantum Genomics, Massy, FR;

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Inventors:

Catherine Llorens-Cortes, Burse sur Yvette, FR;

Yannick Marc, Paris, FR;

Ji Gao-Desliens, Rosny sur Seine, FR;

Fabrice Balavoine, Paris, FR;

Lionel Segard, Massy, FR;

Assignee:

Quantum Genomics, Massy, FR;

Attorney:

Fox Rothschild LLP

Primary Examiner:

Robert S Cabral

Int. Cl.
CPC ...
A61K 31/185 (2006.01); A61K 9/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/567 (2006.01); A61P 9/12 (2006.01); A61K 31/4184 (2006.01); A61K 31/255 (2006.01); A61K 31/4704 (2006.01); A61K 38/00 (2006.01); A61K 31/403 (2006.01); A61K 31/41 (2006.01); A61K 38/05 (2006.01); A61K 31/401 (2006.01); A61K 45/06 (2006.01); A61K 35/74 (2015.01);
U.S. Cl.
CPC ...
A61K 9/00 (2013.01); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 31/185 (2013.01); A61K 31/255 (2013.01); A61K 31/401 (2013.01); A61K 31/403 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4704 (2013.01); A61K 31/567 (2013.01); A61K 35/74 (2013.01); A61K 38/00 (2013.01); A61K 38/005 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); A61P 9/12 (2018.01);
Abstract

The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S')4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.

Find Patent Forward Citations

Loading…